Bone turnover in short-term and long-term home parenteral nutrition for benign disease

Pironi, Loris; Zolezzi, Carola; Ruggeri, E; Paganelli, Federica; Pizzoferrato, Alberto; Miglioli, M.

doi:10.1016/s0899-9007(99)00306-8

Cited by 16 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although net calcium absorption as a percent of oral intake tended to improve during weeks 4 and 12, intestinal calcium absorption was not differ- ent from baseline and was also similar between the control and hGH groups at these time points (Table II). During the unblinded phase (weeks [13][14][15][16][17][18][19][20][21][22][23][24], openlabel hGH was administered for an additional 6 Ϯ 2 weeks in the control subjects and 7 Ϯ 1 weeks in the subjects initially randomized to hGH in the 12-week double-blind phase (NS). Serum 25(OH) D concentrations were similar at week 24 between the 2 study groups (control 23.9 Ϯ 3.0 vs hGH 22.7 Ϯ 5.3 ng/dL; NS), as were serum PTH concentrations (control 75 Ϯ 17 vs hGH 127 Ϯ 57 pg/dL; NS).…”

Section: Serial Calcium and Vitamin D Statusmentioning

confidence: 99%

Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation

Tangpricha

Luo

Fernández‐Estívariz³

et al. 2006

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

Section: Serial Calcium and Vitamin D Statusmentioning

confidence: 99%

Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation

Tangpricha

Luo

Fernández‐Estívariz³

et al. 2006

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…In addition, GLP-2 could decelerate bone losses and diminish osteoporosis often described in these patients [14]. Therefore, native GLP-2 and a dipeptidyl-peptidase IV (DPP-IV) degradation-resistant gly-2 GLP-2 analog [7], Teduglutide, have been evaluated in short-term, “proof of concept” studies in the treatment of SBS patients [15, 16].…”

Section: Introductionmentioning

confidence: 99%

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

Jeppesen

Lund

Gottschalck

et al. 2009

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Background and aims. In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years. Methods. GLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured. Results. GLP-2 compliance was >93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function. Conclusions. GLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.

show abstract

“…To reduce the intake of Al from these additives, the use of calcium chloride has been suggested as a substitute for calcium gluconate 8 , 30 . In fact, calcium chloride has been used in different centers in Europe, 13 , 29 , 32 but due to the higher risk of precipitation with phosphate, calcium gluconate is favored for use in North America. One strategy to reduce the risk of calcium phosphate precipitation is to use an organic source of phosphate more compatible with calcium chloride than inorganic phosphate 2 , 28 .…”

Section: Discussionmentioning

confidence: 99%

Plasma Aluminum Concentrations in Pediatric Patients Receiving Long‐Term Parenteral Nutrition

Courtney‐Martin

Kosar

Campbell

et al. 2014

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

Bone turnover in short-term and long-term home parenteral nutrition for benign disease

Cited by 16 publications

References 26 publications

Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation

Growth Hormone Favorably Affects Bone Turnover and Bone Mineral Density in Patients With Short Bowel Syndrome Undergoing Intestinal Rehabilitation

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function

Plasma Aluminum Concentrations in Pediatric Patients Receiving Long‐Term Parenteral Nutrition

Contact Info

Product

Resources

About